Published in Philos Trans R Soc Lond B Biol Sci on September 19, 2015
Sleep Deprivation Impairs and Caffeine Enhances My Performance, but Not Always Our Performance. Pers Soc Psychol Rev (2016) 0.82
H Lifestyle use of drugs by healthy people for enhancing cognition, creativity, motivation and pleasure. Br J Pharmacol (2017) 0.79
The Effects of Methylphenidate on Resting-State Functional Connectivity of the Basal Nucleus of Meynert, Locus Coeruleus, and Ventral Tegmental Area in Healthy Adults. Front Hum Neurosci (2016) 0.78
Pills or Push-Ups? Effectiveness and Public Perception of Pharmacological and Non-Pharmacological Cognitive Enhancement. Front Psychol (2015) 0.78
Anxiety-potentiated amygdala-medial frontal coupling and attentional control. Transl Psychiatry (2016) 0.78
Why is Cognitive Enhancement Deemed Unacceptable? The Role of Fairness, Deservingness, and Hollow Achievements. Front Psychol (2016) 0.76
Can Neuromodulation also Enhance Social Inequality? Some Possible Indirect Interventions of the State. Front Hum Neurosci (2017) 0.75
New Generation of Psychotherapies Inspired by Cognitive Neuroscience Development: Emergence of Neurocognitive Therapies. Basic Clin Neurosci (2016) 0.75
Psychostimulants As Cognitive Enhancers in Adolescents: More Risk than Reward? Front Public Health (2017) 0.75
Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry (2005) 58.92
Dynamic mapping of human cortical development during childhood through early adulthood. Proc Natl Acad Sci U S A (2004) 17.86
Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry (2010) 16.89
The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry (1976) 15.48
Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clin Neurophysiol (2009) 11.59
Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? Schizophr Bull (2000) 9.62
The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol (2011) 9.40
Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med (2012) 5.64
A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am J Psychiatry (2011) 5.21
A meta-analysis of cognitive remediation in schizophrenia. Am J Psychiatry (2007) 4.78
Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol (2011) 4.63
Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res (1986) 3.86
The mental wealth of nations. Nature (2008) 3.60
Are prescription stimulants "smart pills"? The epidemiology and cognitive neuroscience of prescription stimulant use by normal healthy individuals. Psychol Bull (2011) 3.14
Decision-making processes following damage to the prefrontal cortex. Brain (2002) 3.07
A meta-analysis of cognitive deficits in euthymic patients with bipolar disorder. J Affect Disord (2006) 2.72
Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord (2005) 2.68
Tacrine in Alzheimer's disease. Lancet (1991) 2.67
Major depressive disorder is associated with broad impairments on neuropsychological measures of executive function: a meta-analysis and review. Psychol Bull (2012) 2.65
Methylphenidate enhances working memory by modulating discrete frontal and parietal lobe regions in the human brain. J Neurosci (2000) 2.47
Neurochemical modulation of response inhibition and probabilistic learning in humans. Science (2006) 2.41
Cognitive training for supported employment: 2-3 year outcomes of a randomized controlled trial. Am J Psychiatry (2007) 2.36
Cognition in schizophrenia: core psychological and neural mechanisms. Trends Cogn Sci (2011) 2.31
Modafinil and methylphenidate for neuroenhancement in healthy individuals: A systematic review. Pharmacol Res (2010) 2.26
Cognitive enhancing effects of modafinil in healthy volunteers. Psychopharmacology (Berl) (2002) 2.17
Effects of methylphenidate on spatial working memory and planning in healthy young adults. Psychopharmacology (Berl) (1997) 2.08
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. Mov Disord (2011) 2.05
Should we expand the toolbox of psychiatric treatment methods to include Repetitive Transcranial Magnetic Stimulation (rTMS)? A meta-analysis of the efficacy of rTMS in psychiatric disorders. J Clin Psychiatry (2010) 2.02
Transcranial direct current stimulation in the treatment of major depression: a meta-analysis. Psychol Med (2012) 2.00
Cognitive training and supported employment for persons with severe mental illness: one-year results from a randomized controlled trial. Schizophr Bull (2005) 1.98
The effects of nicotine on attention, information processing, and short-term memory in patients with dementia of the Alzheimer type. Br J Psychiatry (1989) 1.94
Effects of caffeine on human health. Food Addit Contam (2003) 1.84
Atomoxetine improved response inhibition in adults with attention deficit/hyperactivity disorder. Biol Psychiatry (2007) 1.82
Pathological gambling in Parkinson disease is reduced by amantadine. Ann Neurol (2010) 1.79
Therapeutic effects of non-invasive brain stimulation with direct currents (tDCS) in neuropsychiatric diseases. Neuroimage (2013) 1.72
Methylphenidate improves response inhibition but not reflection-impulsivity in children with attention deficit hyperactivity disorder (ADHD). Psychopharmacology (Berl) (2008) 1.71
Neuroplasticity-based cognitive training in schizophrenia: an interim report on the effects 6 months later. Schizophr Bull (2009) 1.69
A systematic review and analysis of long-term outcomes in attention deficit hyperactivity disorder: effects of treatment and non-treatment. BMC Med (2012) 1.67
Computerized cognitive training restores neural activity within the reality monitoring network in schizophrenia. Neuron (2012) 1.67
The size, burden and cost of disorders of the brain in the UK. J Psychopharmacol (2013) 1.62
Battery powered thought: enhancement of attention, learning, and memory in healthy adults using transcranial direct current stimulation. Neuroimage (2013) 1.54
Methylphenidate improves working memory and set-shifting in AD/HD: relationships to baseline memory capacity. J Child Psychol Psychiatry (2004) 1.50
Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions. Depress Anxiety (2013) 1.48
Effects of methylphenidate on cognitive functions in children and adolescents with attention-deficit/hyperactivity disorder: evidence from a systematic review and a meta-analysis. Biol Psychiatry (2013) 1.43
Evolution of neuropsychological dysfunction during the course of schizophrenia and bipolar disorder. Psychol Med (2010) 1.43
Executive function and attention deficit hyperactivity disorder: stimulant medication and better executive function performance in children. Psychol Med (1999) 1.43
Working memory improvement with non-invasive brain stimulation of the dorsolateral prefrontal cortex: a systematic review and meta-analysis. Brain Cogn (2014) 1.42
Modafinil improves cognition and response inhibition in adult attention-deficit/hyperactivity disorder. Biol Psychiatry (2004) 1.38
Cognitive and symptomatic predictors of functional disability in schizophrenia. Schizophr Res (2010) 1.35
Randomized response estimates for the 12-month prevalence of cognitive-enhancing drug use in university students. Pharmacotherapy (2013) 1.32
Does long-term medication use improve the academic outcomes of youth with attention-deficit/hyperactivity disorder? Clin Child Fam Psychol Rev (2012) 1.31
A comprehensive investigation of memory impairment in attention deficit hyperactivity disorder and oppositional defiant disorder. J Child Psychol Psychiatry (2011) 1.28
The psychological well-being of family members of individuals with schizophrenia. Soc Psychiatry Psychiatr Epidemiol (2001) 1.26
The nonmotor symptoms of Parkinson's disease--an overview. Mov Disord (2010) 1.25
Transcranial direct current stimulation: five important issues we aren't discussing (but probably should be). Front Syst Neurosci (2014) 1.24
Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia. Neuropsychopharmacology (2004) 1.23
Computer-assisted cognitive rehabilitation reduces negative symptoms in the severely mentally ill. Schizophr Res (2003) 1.22
Can noninvasive brain stimulation enhance cognition in neuropsychiatric disorders? Neuropharmacology (2012) 1.19
Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study. Mov Disord (2009) 1.16
Assessing cognitive function in clinical trials of schizophrenia. Neurosci Biobehav Rev (2010) 1.16
Repetitive transcranial magnetic stimulation (rTMS) in pharmacotherapy-refractory major depression: comparative study of fast, slow and sham rTMS. Psychiatry Res (1999) 1.13
Neuroenhancement: status quo and perspectives. Eur Arch Psychiatry Clin Neurosci (2008) 1.13
Transcranial stimulation of the developing brain: a plea for extreme caution. Front Hum Neurosci (2014) 1.12
To dope or not to dope: neuroenhancement with prescription drugs and drugs of abuse among Swiss university students. PLoS One (2013) 1.11
Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology (2010) 1.11
Robust resilience and substantial interest: a survey of pharmacological cognitive enhancement among university students in the UK and Ireland. PLoS One (2014) 1.10
Innovative solutions to novel drug development in mental health. Neurosci Biobehav Rev (2013) 1.08
Cognitive impairment in unipolar depression is persistent and non-specific: further evidence for the final common pathway disorder hypothesis. Psychol Med (2008) 1.08
Visuospatial learning and executive function are independently impaired in first-episode psychosis. Psychol Med (2005) 1.08
Cognitive enhancement: promises and perils. Neuron (2011) 1.08
Meta-analysis of the association between cognitive abilities and everyday functioning in bipolar disorder. Bipolar Disord (2012) 1.08
Cognitive training in mental disorders: update and future directions. Am J Psychiatry (2014) 1.07
Hippocampal dysfunction in patients with mild cognitive impairment: a functional neuroimaging study of a visuospatial paired associates learning task. Neuropsychologia (2011) 1.07
Child psychiatry branch of the National Institute of Mental Health longitudinal structural magnetic resonance imaging study of human brain development. Neuropsychopharmacology (2014) 1.06
Impact of modafinil on prefrontal executive function in schizophrenia. Am J Psychiatry (2006) 1.06
The course of functional decline in geriatric patients with schizophrenia: cognitive-functional and clinical symptoms as determinants of change. Am J Geriatr Psychiatry (2003) 1.05
Phenotypic and measurement influences on heritability estimates in childhood ADHD. Eur Child Adolesc Psychiatry (2010) 1.04
Neurocognitive predictors of objective and subjective quality of life in individuals with schizophrenia: a meta-analytic investigation. Schizophr Bull (2010) 1.04
Antidepressant efficacy of two different rTMS procedures. High frequency over left versus low frequency over right prefrontal cortex compared with sham stimulation. Eur Arch Psychiatry Clin Neurosci (2003) 1.04
Playing Super Mario induces structural brain plasticity: gray matter changes resulting from training with a commercial video game. Mol Psychiatry (2013) 1.04
Drug research: a plan for mental illness. Nature (2012) 1.03
The neuropsychology of adult obsessive-compulsive disorder: a meta-analysis. Clin Psychol Rev (2013) 1.02
Neurocognitive effects of methylphenidate in adult attention-deficit/hyperactivity disorder. Psychopharmacology (Berl) (2004) 1.02
Characteristic neurocognitive profile associated with adult attention-deficit/hyperactivity disorder. Psychol Med (2004) 1.00
Pharmacological cognitive enhancement-how neuroscientific research could advance ethical debate. Front Syst Neurosci (2014) 1.00
Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: a randomized controlled pilot study. Schizophr Res (2007) 0.99
Neural correlates of error monitoring modulated by atomoxetine in healthy volunteers. Biol Psychiatry (2010) 0.98
Methylphenidate improves fatigue scores in Parkinson disease: a randomized controlled trial. Mov Disord (2007) 0.98
Impulse control disorders in Parkinson's disease: seeking a roadmap toward a better understanding. Brain Struct Funct (2011) 0.97
Using modafinil to treat fatigue in Parkinson disease: a double-blind, placebo-controlled pilot study. Clin Neuropharmacol (2009) 0.96
Improved executive functioning following repetitive transcranial magnetic stimulation. Neurology (2002) 0.96
A UK strategy for mental health and wellbeing. Lancet (2010) 0.95
Cognitive impairment as a target for pharmacological treatment in schizophrenia. Schizophr Res (1995) 0.95
Atomoxetine acts as an NMDA receptor blocker in clinically relevant concentrations. Br J Pharmacol (2010) 0.95
Transcranial direct current stimulation for major depression: an updated systematic review and meta-analysis. Int J Neuropsychopharmacol (2014) 0.95
Combining computerized social cognitive training with neuroplasticity-based auditory training in schizophrenia. Clin Schizophr Relat Psychoses (2013) 0.94
What have we learned from recent twin studies about the etiology of neurodevelopmental disorders? Curr Opin Neurol (2013) 0.93
Prevalence of stimulant use in a sample of US medical students. Ann Clin Psychiatry (2013) 0.91
Neuroscience: transcranial devices are not playthings. Nature (2013) 0.91
Cognitive enhancement drug use among future physicians: findings from a multi-institutional census of medical students. J Gen Intern Med (2013) 0.91